NLRP3 and metabolic dysfunction-associated steatotic liver disease: NLRP6, NLRP3, and the effector protein IL-18 could negatively regulate the progression of NAFLD/NASH by modulating the gut microbiota, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated NAFLD [82].